A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
Completed
- Conditions
- Non-Valvular Atrial Fibrillation (NVAF)
- Registration Number
- NCT05027061
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 11776
Inclusion Criteria
• Participants received medical treatment for NVAF between 10-Jan-2012 and 31-Aug-2020.
Exclusion Criteria
- Had no data of serum creatinine in the participant's medical records
- Had no data of body weight in the participant's medical records
- Were given oral anticoagulant (OAC) for treatment of diseases other than atrial fibrillation (AF)
Other protocol-defined inclusion/exclusion criteria apply.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Distribution of outcomes of NVAF participants: Pulse rate At Baseline Distribution of socio-demographic characteristics of NVAF participants: Age group At Baseline Distribution of socio-demographic characteristics of NVAF participants: Height At Baseline Distribution of outcomes of NVAF participants: Degree of life freedom At Baseline Distribution of clinical characteristics of NVAF participants: Risk factors for bleeding At Baseline Distribution of medication prescribed during baseline: angiotensin-converting enzyme inhibitor (ACE) At Baseline Distribution of medication prescribed during baseline: Antiarrhythmic drug At Baseline Distribution of medication prescribed during baseline: H2-receptor antagonist At Baseline Distribution of clinical characteristics of NVAF participants: Comorbidities At Baseline Specialization of the treating physician At Baseline Distribution of socio-demographic characteristics of NVAF participants: Gender At Baseline Distribution of outcomes of NVAF participants: Systolic and diastolic blood pressure At Baseline Distribution of medication prescribed during baseline: angiotensin-receptor blocker (ARB) At Baseline Distribution of socio-demographic characteristics of NVAF participants: Body weight At Baseline Distribution of outcomes of NVAF participants: Drinking information At Baseline Distribution of outcomes of NVAF participants: Smoking information At Baseline Distribution of outcomes of NVAF participants: Hospitalization/outpatient status At Baseline Distribution of clinical characteristics of NVAF participants: Risk factors for stroke At Baseline Distribution of outcomes of NVAF participants: OAC prescription and administration status At Baseline Distribution of medication prescribed during baseline: Statin At Baseline Distribution of medication prescribed during baseline: P2Y12 inhibitor At Baseline Distribution of medication prescribed during baseline: Other antiplatelet drugs At Baseline Distribution of medication prescribed during baseline: Other anticoagulants At Baseline Distribution of socio-demographic characteristics of NVAF participants: Body mass index (BMI) At Baseline Distribution of outcomes of NVAF participants: Internal medical device information At Baseline Distribution of medication prescribed during baseline: calcium antagonist At Baseline Distribution of medication prescribed during baseline: proton pump inhibitor (PPI) At Baseline Distribution of medication prescribed during baseline: aspirin At Baseline Distribution of medication prescribed during baseline: P-glycoprotein inhibitor At Baseline
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Local Institution
🇯🇵Tokyo, Japan